Showing results (131-140 of 202) with videos related to

Sort By:
Pageof 21
ESMO Open|October 16, 2025
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancerG Antonarelli, M Milano, C Andreon, et al.
Annals of Surgical Oncology|December 18, 2014
Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of OncologyM Intra, G Viale, J Vila, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsM Colleoni, A Rocca, M T Sandri, et al.
Breast Cancer Research and Treatment|November 9, 2011
Prognostic role of CA15.3 in 7942 patients with operable breast cancerM T Sandri, M Salvatici, E Botteri, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 28, 2025
Invasive Pleomorphic Lobular Carcinoma of the breast: Clinicopathological features, treatment patterns and outcomesN Peradze, A Polizzi, E Pagan, et al.
ESMO Open|December 11, 2025
Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort studyC Valenza, N Bianco, M Milano, et al.
Breast Cancer Research and Treatment|September 27, 2005
Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgeryG Curigliano, J Y Petit, F Bertolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Very young women (<35 years) with operable breast cancer: features of disease at presentationM Colleoni, N Rotmensz, C Robertson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2006
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative diseaseM Colleoni, N Rotmensz, G Peruzzotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncologyM De Laurentiis, G Cancello, L Zinno, et al.
Pageof 21